Mayne Pharma Group Ltd (ASX: MYX) announced today that it has completed the acquisition of generic Efudex (fluorouracil cream 5%) from Spear Pharmaceuticals.
Here are the highlights of the acquisition:
- Acquisition price of US$20 million comprising US$16 million in cash and US$4 million in Mayne Pharma equity
- An additional US$10 million in deferred contingent payments (depending on market conditions over the next three years)
- A long term supply agreement with the current US based manufacturer
- The acquisition is Earnings Per Share (EPS) accretive and has an implied EBITDA multiple in the “low single digits”
- Mayne Pharma will fund the acquisition through a combination of cash and undrawn debt
Mayne decided to proceed with the acquisition because generic Efudex has a fairly sizeable and growing market.
The cream treats actinic keratoses (a condition caused by cumulative sun exposure) which, according to the company’s announcement, affects 60 million Americans.
The annual market sales for generic Efudex are estimated at US$66 million with volumes growing at 10% per annum over the last five years according to IQVIA.
Spear’s generic Efudex (the one acquired by Mayne Pharma) had calendar 2018 Q1 net sales of US$3 million.
Whilst the acquisition won’t make much of an initial impact on Mayne Pharma’s $1.3 billion market cap, shareholders will be pleased that it is at least earnings accretive and with the potential of some further upside as the market is growing.
Despite that, I’m not a buyer of Mayne Pharma shares. It’s been one of the most shorted stocks on the ASX and its share price has lost over 50% of its value in the last two years as the company battled generic drug price deflation which led to significant losses.
Other ASX pharma stocks such as Australian Pharmaceutical Industries Ltd (ASX: API) have also under-performed.
New product launches and acquisitions may eventually pull Mayne Pharma back up, but I think there are better opportunities elsewhere. For example, this FREE REPORT identifies a high flying smaller healthcare company that has outperformed Mayne Pharma and the market.
The ASX small cap up 285% with no sign of stopping...
One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 – with no signs of stopping...
To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.
Click here to claim your free report.
You can find Kevin on Twitter @KevinGandiya.
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.